In recent years, the world has been hit by a surge of drug-resistant fungi, including the notorious Candida auris. These fungal infections are becoming increasingly difficult to treat and have already caused severe health problems and even deaths. Despite this, the public remains largely unaware of the extent of the problem, and governments have been reluctant to take action. However, experts warn that the window to prevent a major global health crisis is rapidly closing, and urgent action is needed to address the growing threat of deadly drug-resistant fungi. This article will explore the rise of drug-resistant fungi and the implications of inaction, as well as potential solutions to this critical public health issue.
The Centers for Disease Control and Prevention (CDC) has issued a warning about Candida auris, a fungal infection that is spreading in US healthcare facilities. The deadly fungus often does not respond to traditional antifungal drugs, with southern Nevada emerging as a hotspot of infections. The CDC has reported that between 30-60% of those infected with the fungus have died. Unlike zombies in popular culture, a strain on healthcare systems and increased mortality rates are the likely outcomes of an outbreak. To mitigate the risk of antifungal-resistant pathogens, the CDC recommends that appropriate steps are taken to track, monitor and stop fungal pathogens that can infect people and resist current treatments.
Fungi has largely evolved to survive in the natural environment and only seldom caused infections in humans until after the 1980s. Since then, there has been a significant increase in fungal infections, including newly recognised species and strains that can resist antifungal drugs. While there may only be around 300 fungal pathogens that can currently infect humans, this only accounts for a fraction of the approximately 5 million fungal species present in the environment. As our environment changes, more fungi may adapt, spread, and potentially infect humans, including new fungal pathogens that emerge, infect large populations and resist treatment.
The first step in mitigating the risk of antifungal-resistant pathogens is to conduct robust surveillance of fungal pathogens. While estimates show that Aspergillus causes 15,000 hospitalisations and 800 deaths each year in the United States, the real numbers are likely higher than these estimates. The second problem is the over-reliance on current antifungal drugs, as the more they are used, the more antifungal-resistant strains of pathogens can emerge. Antifungals are even overused in plant agriculture, with powdered fungicides used as pesticides. Potentially, the same resistance problems can occur in the agricultural industry.
Given the potential for fungicide used in agriculture to promote antifungal-resistant strains of Aspergillus, caution is needed. Current overuse of antifungals in agriculture is largely unregulated, with there being a communication breakdown among agencies tasked with assessing and regulating antifungal use. The EPA continues to approve the expansion of fungicide use, which could render critical human drugs ineffective even before they are used for treatment. However, appropriate measures such as withdrawing fungicide approval in agriculture and restricting the use of antifungals specifically to human medicine could help to mitigate these risks.
As the threat of drug-resistant fungi like Candida auris continues to loom, the window to act is rapidly closing. The clock is ticking to find new treatments, prevent infections, and encourage responsible use of antibiotics. It’s up to us to take action now, before it’s too late. Let’s work together to ensure a safer, healthier future for ourselves and future generations.
